Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates : Episode 14
Opinion
Video
Challenges and Learnings from EVOKE-01
Author(s):
Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.
EP: 1.Treatment Strategies for NSCLC with Non-Actionable Mutations
EP: 2.Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02
EP: 3.Exploring the TROPION-Lung04 Study
EP: 4.Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC
EP: 5.Navigating Between ADCs in NSCLC
EP: 6.Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2
EP: 7.Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC
EP: 8.MARIPOSA Study Insights
EP: 9.Optimizing Therapy Selection in EGFR Mutant NSCLC
EP: 10.ASCO 2024 Updates: Novel Approaches in NSCLC Therapy
EP: 11.Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC
EP: 12.Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape
EP: 13.Targeting of HER3: Insights from HERTHENA-Lung01
Now Viewing
EP: 14.Challenges and Learnings from EVOKE-01
EP: 15.Key ADC Studies at ASCO 2024
EP: 16.Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd
EP: 17.Patient Selection and Sequencing of NSCLC ADCs
- Please review the rationale and study design for EVOKE-01 evaluating sacituzumabgovitecan in patients with NSCLC with disease progression following platinum-based chemotherapy and checkpoint inhibitors. (Garassino, et al. ASCO 2022. Abstract TPS9149)
- Briefly outline the study design and key endpoints.
- Jan 2024 Press Release; Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC)
- ASCO 2024 Data: Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study
Related Videos
Related Content
